ENTRY       D09889                      Drug
NAME        Dulaglutide (USAN/INN);
            Dulaglutide (genetical recombination) (JAN);
            Trulicity (TN)
PRODUCT     TRULICITY (A-S Medication Solutions)
            TRULICITY (A-S Medication Solutions)
            TRULICITY (A-S Medication Solutions)
            TRULICITY (A-S Medication Solutions)
            TRULICITY (A-S Medication Solutions)
            TRULICITY (A-S Medication Solutions)
            TRULICITY (Eli Lilly and Company)
FORMULA     C2646H4044N704O836S18
EXACT_MASS  59633.0544
MOL_WEIGHT  59669.84
SEQUENCE    HGEGTFTSDV SSYLEEQAAK EFIAWLVKGG GGGGGSGGGG SGGGGSAESK YGPPCPPCPA
            PEAAGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP
            REEQFNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL
            PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT
            VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLG
            (Disulfide bridge: 90-150, 196-254, 55-55', 58-58')
  TYPE      Peptide
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG01493  GLP-1 receptor agonist
REMARK      Therapeutic category: 2499
            ATC code: A10BJ05
            Product: D09889<JP/US>
EFFICACY    Antidiabetic, Glucagon-like peptide 1 (GLP-1) receptor agonist
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
  TYPE      Modified peptide
COMMENT     Fc fusion protein of GLP-1 [HSA:2641] [KO:K05259] analog
            Treatment of type II diabetes
TARGET      GLP1R [HSA:2740] [KO:K04581]
  PATHWAY   hsa04080(2740)  Neuroactive ligand-receptor interaction
            hsa04911(2740)  Insulin secretion
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BJ Glucagon-like peptide-1 (GLP-1) analogues
                 A10BJ05 Dulaglutide
                  D09889  Dulaglutide (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Agents
               GLP-1 Receptor Agonist
                Dulaglutide
                 D09889  Dulaglutide (USAN/INN)
             Kidney Agents
              GLP-1 Receptor Agonist
               Dulaglutide
                D09889  Dulaglutide (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              24  Hormones
               249  Miscellaneous
                2499  Others
                 D09889  Dulaglutide (USAN/INN); Dulaglutide (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG01493  GLP-1 receptor agonist
                D09889  Dulaglutide
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Secretin receptor family
               Glucagon
                GLP1R
                 D09889  Dulaglutide (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09889
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09889
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09889
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09889
DBLINKS     CAS: 923950-08-7
            PubChem: 124490606
///